217 related articles for article (PubMed ID: 25329375)
1. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Takahashi S; Homma Y; Urano T; Aburatani H; Inoue S
Mol Endocrinol; 2014 Dec; 28(12):2012-24. PubMed ID: 25329375
[TBL] [Abstract][Full Text] [Related]
2. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
3. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
5. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.
Grabowska MM; Kelly SM; Reese AL; Cates JM; Case TC; Zhang J; DeGraff DJ; Strand DW; Miller NL; Clark PE; Hayward SW; Gronostajski RM; Anderson PD; Matusik RJ
Endocrinology; 2016 Mar; 157(3):1094-109. PubMed ID: 26677878
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
7. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
8. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.
Zhao Y; Tindall DJ; Huang H
Int J Biol Sci; 2014; 10(6):614-9. PubMed ID: 24948874
[TBL] [Abstract][Full Text] [Related]
9. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
[TBL] [Abstract][Full Text] [Related]
10. Modulation of androgen receptor transactivation by FoxH1. A newly identified androgen receptor corepressor.
Chen G; Nomura M; Morinaga H; Matsubara E; Okabe T; Goto K; Yanase T; Zheng H; Lu J; Nawata H
J Biol Chem; 2005 Oct; 280(43):36355-63. PubMed ID: 16120611
[TBL] [Abstract][Full Text] [Related]
11. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis.
van Boxtel R; Gomez-Puerto C; Mokry M; Eijkelenboom A; van der Vos KE; Nieuwenhuis EE; Burgering BM; Lam EW; Coffer PJ
Cell Death Differ; 2013 Sep; 20(9):1219-29. PubMed ID: 23832113
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
13. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.
Sutinen P; Rahkama V; Rytinki M; Palvimo JJ
Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374
[TBL] [Abstract][Full Text] [Related]
14. CR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction.
Suh JH; Shong M; Choi HS; Lee K
Mol Endocrinol; 2008 Jan; 22(1):33-46. PubMed ID: 17885209
[TBL] [Abstract][Full Text] [Related]
15. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.
Grabowska MM; Elliott AD; DeGraff DJ; Anderson PD; Anumanthan G; Yamashita H; Sun Q; Friedman DB; Hachey DL; Yu X; Sheehan JH; Ahn JM; Raj GV; Piston DW; Gronostajski RM; Matusik RJ
Mol Endocrinol; 2014 Jun; 28(6):949-64. PubMed ID: 24801505
[TBL] [Abstract][Full Text] [Related]
16. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
17. The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer.
Hu Z; Zhu L; Tan M; Cai M; Deng L; Yu G; Liu D; Liu J; Lin B
Biochimie; 2015 Feb; 109():42-8. PubMed ID: 25500588
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
Cheng Y; Wang D; Jiang J; Huang W; Li D; Luo J; Gu W; Mo W; Wang C; Li Y; Gu S; Xu Y
Prostate; 2020 May; 80(8):640-652. PubMed ID: 32282098
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
20. Regulated expression of the TPĪ² isoform of the human T prostanoid receptor by the tumour suppressors FOXP1 and NKX3.1: Implications for the role of thromboxane in prostate cancer.
O'Sullivan AG; Eivers SB; Mulvaney EP; Kinsella BT
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3153-3169. PubMed ID: 28890397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
